Kairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105
15/7 16:39
(RTTNews) - Shares of Kairos Pharma, Ltd. (KAPA) are currently trading 88.2937 percent higher after announcing positive interim safety results from its ongoing Phase 2 trial of ENV-105 or Carotuximab in patients with metastatic castration-resistant prostate cancer known as mCRPC....